---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-143748"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2021-11-26T23:59:59+00:00"
generated_at: "2026-06-28T05:15:29.746096+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ANI closes Novitium buy for $89.5M cash + shares; $300M loan & $25M PIPE

## Summary
- Consideration: $89.5M cash + 2.47M shares + up to $46.5M earn-out.
- New financing: $300M Term Loan (Truist) + $40M revolver + $25M PIPE from Ampersand.
- Appoints Novitium co-founders: Samy Shanmugam as Head of R&D/COO & director; Chad Gassert as SVP Corp Dev.
- Pro-forma YTD Sep 30 revenue $202.5M; non-GAAP EBITDA $66.6M; immediately accretive to adj. EPS.
- Novitium pipeline: 20+ launches in 18 months, 13 approvals since March 2021, including CGT products.

## SEC filing metadata
- accession: 0001104659-21-143748
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2021-11-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 2.03, 3.02, 5.03, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/0001104659-21-143748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/tm2133555d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-143748
- JSON: https://secwatch.observer/filing/0001104659-21-143748.json
- Plain text: https://secwatch.observer/filing/0001104659-21-143748.txt

## Key facts
- Executive change
  Muthusamy Shanmugam was appointed as Head of Research & Development and Chief Operating Officer–Novitium Operations at ANI PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Head of Research & Development and Chief Operating Officer–Novitium Operations
  source text: On the Closing Date, in connection with the consummation of the Acquisition, the Company announced the appointment of Muthusamy Shanmugam, age 54, as Head of Research & Development and Chief Operating Officer–Novitium Operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/0001104659-21-143748-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.